14 Matching Annotations
  1. Nov 2018
    1. Nimodipine controlled the escalation of the morphine dose in 9 patients (65%), and placebo in 4 (28%), the difference being statistically significant (P=0.03). The dose of morphine was reduced from 313±52 to 174±33 mg/day (P<0.001) in the nimodipine group, and from 254±26 to 218±19 mg/day (not significant) in the placebo group.

      Nimodipine reduced morphine dose in already tolerant patients.

  2. Dec 2015
    1. RAJ: Yes and no. Time does not function in the limited way in which you conceive it. I will go into that at another time. Suffice it to say that although you will perceive the communication as occurring simultaneously with your end of the conversation, my end of the conversation takes place when it is convenient for me. It is then slotted into your time reference at the appropriate moments.

      How Time works from Raj's perspective.

    2. RAJ: Yes and no. I am not speaking directly with you. I am, you might say, speaking to you in meanings without language. If I were to communicate with someone in India they would hear me in their language, and yet I would not be speaking to them in any language at all, just meanings. The more you become integrated with your experience through the technique you are now using, the more accurate will be your “translation” and the more easily it will flow. Right now, my meanings are flowing fluidly, but the fact that your typewriter is stuttering is due to your awkwardness and lack of experience in communication on this level of consciousness.

      Raj is communicating meaning, not language. He describes this later in the book saying that Being unfolds as meaning - not language.

    1. It is true that you are not participating in spiritualism. You are not communicating with a soul that has “passed on.” You are not speaking to an individuality still befuddled by the three-dimensional illusion of birth and death who thinks that he was ever born or ever died. I am not the medium through which the Christ-consciousness is revealing Itself as your conscious experience of Being. But, I do exist, as does every other individualization who has existed as an infinite aspect of Fourth-dimensional Conscious Being. There is infinite progression, even beyond the partial, three-dimensional-only view. It is simply ignorance—the inability to see infinitely—which would make one think that once the “mortal dream” is grown out of, there does not continue to be the infinite unfolding of Being as Conscious Being. This is true before or after the experience called death.

      Definition: Ignorance - the inability to see infinitely.

      More about Raj - not caught in belief of birth and death.

      There is an infinite progression of the unfolding of Being as Conscious Being. "Death" does not end it - it never ends.

      This is implied by WOM when it speaks of *The journey to the Kingdom and the Journey within the Kingdom."

  3. Nov 2015
    1. In fact, the more you can find your answers coming from that which you recognize to be your own Being, without any possibility of imagining that it is coming from someone or something separate from yourself—such as me—the better it will be for you in tying together those aspects of your Being which you have not consciously been aware of as Your Self. The fact is that it is all You. But, it must become your conscious experience of your Being, without any dichotomy of any kind.

      I have to find my own way.

      You must become your conscious experience of your Being without any dichotomy of any kind.

  4. Jul 2015
    1. It is clear from the use of ES2 and RMG-II cell lines that the Atlas Antibodies ARID1A antibody is specific for ARID1A in both Western blots and formalin-fixed paraffin embedded preparations of human origin and, coupled with the literature evidence, that it is validated in human tissue.

      Validation statement RRID:AB_1078205 Summary

    2. A No Primary antibody control (NPA) showed no staining in the epithelial or nuclear compartment (Figure 3B; Dataset e).

      Validation statement RRID:AB_1078205 No primary control

    3. There was no cytoplasmic or extracellular stromal background staining present and the antibody titrated successfully losing the intensity of staining, as expected

      Validation statement RRID:AB_1078205 Titration curve

    4. Control slides, omitting the primary antibody, were negative except for the ER2 condition in the RMG-II cell pellet where a weak cytoplasmic background could be seen (Figure 2; Dataset d). Thus there was minimal background inherent in the staining procedure. It was therefore determined that the antibody showed specificity for formalin-fixed paraffin embedded tissues and could be run on murine tissue.

      Omission of primary antibody

      Validation statement RRID:AB_1078205

    5. Using Western blot and IHC on murine wild-type and knockout tissue we have demonstrated that this antibody to ARID1A correctly stains murine tissue by immunohistochemistry.

      Validation claim

    6. It could be demonstrated that the HPA ARID1A antibody showed positive expression in ES-2 cell lines at the expected size of 270 kDa and no staining for RMG-II.

      Validation statement for RRID:AB_1078205

  5. Apr 2015
    1. Patient groups, lastly, could write open letters to all companies and researchers withholding methods and results of trials on treatments taken by their members, represent their constituencies by holding individuals to reasonable account, and again help improve compliance.

      Hmmm. Perhaps annotation would be a better mechanism.

    2. This negates a key defence commonly cited by trialists and sponsors when facing calls for greater transparency: that journals reject “negative” results. All trials can now be reported, immediately, using clinicaltrials.gov as a first or last resort, if the trialist is willing. The question remains: how can we ensure this is done?

      Raises the question about whether regulatory agencies could use annotations, as part of Resource Watch, to question whether data that should have been released was released.